



# Typhoid conjugate vaccine introduction cost to countries and support from Gavi, the Vaccine Alliance

The World Health Organization recommends TCV introduction for infants and children over 6 months of age as a single dose, and where feasible, a single dose catch-up of children up to 15 years of age.

	ROUTINE IMMUNIZATION				CAMPAIGN		
<b>TARGET POPULATION</b>	 Infants & children older than 6 months <sup>1</sup>				 Up to 15 years old		
<b>VACCINE PRICE PER DOSE<sup>2</sup></b>	\$1.39				\$1.39		
<b>COST TO COUNTRY<sup>3</sup></b>							
<b>VACCINE PRICE PER DOSE TO THE COUNTRY</b>	<b>Co-financing based on transition phase</b>				<b>\$0</b> Procurement of vaccines and immunization supplies fully supported by Gavi		
	<i>Initial self-financing</i>	<i>Preparatory transition</i>	<i>Accelerated transition<sup>4</sup></i>	<i>Fully self-financing</i>			
	\$0.20	Based on country specific price fraction	Based on country specific price fraction	\$1.39			
<b>PAID BY GAVI</b>							
<b>PROGRAMMATIC SUPPORT FROM GAVI</b>	<b>Vaccine Introduction Grant (VIG)</b> Dependent on country transition phase				<b>Operational support for campaigns (Ops)</b> Dependent on country transition phase		
	<i>Initial self-financing</i>	<i>Preparatory transition</i>	<i>Accelerated transition</i>	<i>Initial self-financing</i>	<i>Preparatory transition</i>	<i>Accelerated transition</i>	
	\$0.80 per infant in the birth cohort in year of introduction, or a lump sum of US\$100,000, whichever is higher	\$0.70 per infant in the birth cohort in year of introduction, or a lump sum of US\$100,000, whichever is higher	\$0.60 per infant in the birth cohort in year of introduction, or a lump sum of US\$100,000, whichever is higher	\$0.65 per targeted person	\$0.55 per targeted person	\$0.45 per targeted person	

<sup>1</sup> Gavi encourages countries to integrate TCV into routine immunization schedules based on the WHO recommendation and national guidelines. Older children may be vaccinated during a routine immunization if earlier vaccination is missed.

<sup>2</sup> Price per dose is based on the Gavi-supported 5-dose vial presentation and is a weighted average price of the currently available TCV products.

<sup>3</sup> Financing for syringes and safety boxes follows the same cost formula as the vaccine.

<sup>4</sup> During accelerated transition, the co-financing requirement increases each year during the 8 year transition period.

All costs are in US dollars.